AAA
TRML

Affinity Asset Advisors’s Tourmaline Bio TRML Stock Holding History

Affinity Asset Advisors’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$1.15M – 121
2024
Q1 		$1.15M Sell
50,000
-18,081
-27% -$638K 0.14% 82
2023
Q4 		$1.78M Buy
68,081
+28,081
+70% +$562K 0.33% 57
2023
Q3 		$1.12M Buy
40,000
+20,000
+100% +$586K 0.32% 56
2023
Q2 		$608K Buy
+20,000
New +$511K 0.21% 62

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Affinity Asset Advisors's TRML Position: Q2 2024 in Review

Affinity Asset Advisors sold out of Tourmaline Bio (TRML) in Q2 2024, closing a stake of 50,000 shares — an estimated $1.15M sold.

Affinity Asset Advisors first reported a position in TRML in Q2 2023 and held it in 4 quarters. The position peaked at $1.78M in Q4 2023. 84 funds tracked by Wall St. Rank hold TRML as of Q2 2024.

  • Affinity Asset Advisors reported no remaining Tourmaline Bio position as of Q2 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 50,000 Tourmaline Bio shares in Q2 2024, an estimated $1.15M.
  • Affinity Asset Advisors first reported a position in Tourmaline Bio in Q2 2023 and held it in 4 quarters.
  • Affinity Asset Advisors's Tourmaline Bio position peaked at $1.78M in Q4 2023.
  • 84 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2024.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.